INTRODUCTION
============

DNA methylation is a core epigenetic process that influences a wide variety of biological mechanisms, including gene expression, chromosomal stability, imprinting, and cellular differentiation ([@b3-molcell-37-6-467]). Methylation can mediate environmental influences on gene expression and can modulate disease risk associated with genetic variation ([@b12-molcell-37-6-467]). Abnormal DNA methylation patterns (including genome-wide hypomethylation and gene-specific hypo- and hypermethylation) have been shown to be associated with a range of health outcomes ([@b23-molcell-37-6-467]). In cancer and certain other diseases, most of these changes have been observed at the tissue level ([@b10-molcell-37-6-467]; [@b30-molcell-37-6-467]). Data relating to whether DNA methylation changes in peripheral blood cells can serve as useful, informative biomarkers for different health outcomes is much more limited, but new information is rapidly emerging ([@b14-molcell-37-6-467]). A number of methods are available for the analysis of global DNA methylation levels \[total content of 5-methylcytosine (5-mC)\] ([@b35-molcell-37-6-467]). There are over 500,000 long-interspersed nuclear elements (LINEs) and 1,500,000 short-interspersed nuclear elements (SINEs) across the human genome. Alu elements are the most common SINE; comprising 11% the human genome and containing a third of all methylation sites ([@b9-molcell-37-6-467]). The substantial representation of these repetitive elements throughout the genome makes their effectiveness as proxies for global DNA methylation highly evident. Indeed, methylation levels in Alu and LINE-1 repeats have been shown in previous studies to be associated with total genomic methylation content ([@b40-molcell-37-6-467]; [@b43-molcell-37-6-467]). Estimates of these are increasingly being used in epidemiological investigations owing to their relatively low-cost, high-throughput, and the fact that they can offer quantitative results ([@b40-molcell-37-6-467]). Interestingly, global methylation measures in blood DNA have been shown to vary in relation to demographic and lifestyle characteristics, including age, sex, smoking status, alcohol consumption, physical activity, and diet ([@b14-molcell-37-6-467]; [@b50-molcell-37-6-467]). However, there are still few studies of the relationship between DNA methylation and weight status.

Obesity is simply defined as a condition of abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired. Obesity is the result of the interplay between external (environmental) and internal (genetic) factors. It has been cited as the epidemic of our time, with obesity rates sharply and steadily rising in many parts of the world, leading to increased morbidity and mortality due to type 2 diabetes and cardiovascular disease ([@b8-molcell-37-6-467]). Obesity-related mortality by far exceeds mortality caused by other common diseases ([@b1-molcell-37-6-467]). Moreover, about 20% of all cancers are caused by overweight, and obesity has been shown to be associated with increased risk and worse outcomes following diagnosis ([@b42-molcell-37-6-467]). Furthermore, the incidence of some types of cancer have been shown to be strongly associated with body mass index (BMI), which has historically been used to define obesity ([@b29-molcell-37-6-467]). Our understanding of how and why obesity develops is incomplete. To date, several studies concerning DNA methylation and obesity have focused primarily on gene-specific methylation and had relatively small sample sizes ([@b7-molcell-37-6-467]; [@b11-molcell-37-6-467]; [@b13-molcell-37-6-467]; [@b22-molcell-37-6-467]; [@b39-molcell-37-6-467]). Currently, studies of global methylation levels in blood DNA and BMI have yielded inconsistent results ([@b18-molcell-37-6-467]; [@b24-molcell-37-6-467]; [@b26-molcell-37-6-467]; [@b39-molcell-37-6-467]; [@b47-molcell-37-6-467];[@b48-molcell-37-6-467]; [@b50-molcell-37-6-467]). BMI is now considered to be an important determinant of methylation biomarkers in the blood of women of reproductive age ([@b37-molcell-37-6-467]). Interestingly, recent evidence has shown that alterations in global DNA methylation may be an important contributor to incidence risk of cancer and cardiovascular disease ([@b2-molcell-37-6-467]; [@b35-molcell-37-6-467]). In this study, in order to investigate the specific effects of BMI on global DNA methylation and develop blood-based biomarker as initial screening test for obesity-related disease, we quantified the methylation of Alu elements in the peripheral blood DNA of 244 women with a range of BMIs using pyrosequencing technology.

MATERIALS AND METHODS
=====================

Study population
----------------

Study subjects were 244 apparently healthy women aged between 20 and 51 years (mean 32 ± 7.9 years). This study was approved by the Institutional Review Board of Kyungpook National University Hospital. Additionally, informed written consent was obtained from all subjects before they participated in the study. Demographic information and lifestyle factors were determined for all participants by trained interviewers using a standardized questionnaire *via* face-to-face interviews. Height and bodyweight were measured using standard methods with participants wearing light clothes. BMI is easy to obtain \[calculated by weight divided by height squared (kg/m^2^)\] and is considered to be an acceptable proxy for under and overweight. BMI has also been shown to be directly related to health risks and mortality in many populations. According to the current international standard (WHO 1998), a BMI of over 25 kg/m^2^ is considered to indicate overweight and a BMI of over and 30 kg/m^2^ is considered to indicate obesity. However, the BMI cutoff values for overweight and obesity vary in Asian populations from 22 to 25 kg/m^2^ and the increased risk of co-morbidities conferred by obesity have been shown to occur at a lower BMI in several Asian populations ([@b21-molcell-37-6-467]). We therefore divided the participants into 3 categories based on BMI normal weight (BMI \< 23 kg/m^2^), overweight (23 kg/m^2^ ≤ BMI \< 30 kg/m^2^), and obese (BMI ≥ 30 kg/m^2^). Blood samples were obtained *via* venipuncture after overnight fasting, and serum samples were separated by centrifugation and transferred to uncontaminated bottles with Teflon-coated caps. All samples were kept frozen at −70°C until analyses were conducted. Clinical laboratory values were determined by standard biochemical automatic or semi-automatic methods.

Blood DNA extraction and bisulfite treatment
--------------------------------------------

Genomic DNA was extracted from whole-blood samples using a QIAamp DNA Blood Kit (Qiagen, USA). One microgram DNA was bisulfite-modified using an EZ DNA Methylation-Gold Kit (Zymo Research, USA) according to the manufacturer's instructions. Final elution was performed with 30 μl M-Elution Buffer (Zymo Research) and was stored at −70°C until analyzed. Built-in analysis of non-CpG cytosine residues provided an internal control for the completeness of bisulfate treatment. Following treatment with bisulfite, the conversion of this C into T is expected to be 100%. It is possible to insert a C/T single-nucleotide polymorphism into the sequence to be analyzed, and this will result in 100% Ts if conversion is efficient.

Assay of Alu methylation
------------------------

Alu methylation analysis was quantitatively performed on the bisulfite-treated DNA using pyrosequencing with the polymerase chain reaction (PCR) primers and conditions previously described ([@b5-molcell-37-6-467]). In brief, the bisulfite-treated samples (50 ng) were amplified with a biotin-labeled primer *via* PCR, which enables the conversion of the PCR product to a single-stranded DNA template suitable for pyrosequencing. Confirmation of the quality of the PCR products and their freedom from contamination was established on 2% agarose gels with ethidium bromide staining. After purification of PCR products using Sepharose beads on PyroMark Vacuum Prep Workstation (Qiagen), pyrosequencing was carried out using the PyroMark Q96MD System (Qiagen) according to manufacturer's instructions, including a single-strand binding protein. The percentage of methylatation was expressed for each DNA locus as % 5-mC divided by the sum of methylated and unmethylated cytosines. We tested each marker 3 times and used the average percentage in the statistical analysis. Three controls were included in every pyrosequencing run. One well was filled with water to ensure no contamination, and 2 wells were filled with CpGenome Universal methylated and unmethylated DNA (Chemicon, USA) to evaluate the repeatability of the assay.

Statistical analysis
--------------------

Statistical analysis and plotting was performed using R version 2.15.3 (<http://www.r-project.org>). Continuous variables were compared using one-way analysis of variance or analysis of covariance and pairwise *post hoc* comparison identified statistical differences following Bonferroni adjustment. Categorical variables were compared using a chi-squared test.

RESULTS AND DISCUSSION
======================

Growing evidence indicates that there are sex differences in global DNA methylation in the blood ([@b35-molcell-37-6-467]; [@b50-molcell-37-6-467]). We have chosen healthy women as study subjects. First, overweight and obesity pose more serious health challenge to women than men. Obesity is a common disorder affecting approximately 1 in 3 women and the prevalence of extreme obesity is about 50% higher among women than men ([@b31-molcell-37-6-467]). Moreover, prevalence of metabolic syndrome is associated with obesity and its escalation has been steeper in women, particularly in young women ([@b28-molcell-37-6-467]). Second, recent result has shown that BMI is a strong determinant of methylation biomarkers in women of child-bearing age ([@b37-molcell-37-6-467]), indicating a greater likelihood of BMI effects on global DNA methylation in women. Finally, previous studies investigating the effect of BMI on global DNA methylation include mainly male populations ([@b50-molcell-37-6-467]). In addition, we have found that Alu assays may be a more sensitive method for detecting global DNA hypomethylation in peripheral blood leukocytes in the general population than LINE-1 assays ([@b18-molcell-37-6-467]). Most studies have focused primarily on LINE-1 methylation as a surrogate for global DNA methylation ([@b24-molcell-37-6-467]; [@b26-molcell-37-6-467]; [@b47-molcell-37-6-467]; [@b48-molcell-37-6-467]). In this study, we determined Alu methylation levels in a population of Korean women. The characteristics of the study population are shown in [Table 1](#t1-molcell-37-6-467){ref-type="table"}. Obese participants had higher baseline hemoglobin, serum glutamic-oxaloacetic transaminase (GOT), serum glutamicpyruvic transaminase (GPT), total cholesterol (TC), and triglyceride (TG) levels than normal weight and overweight participants. Scatter plot and linear regression analyses showed that these biochemical parameters were positively correlated with BMI ([Fig. 1](#f1-molcell-37-6-467){ref-type="fig"}), which is consistent with recent observations that GOT and GPT levels are strongly associated with BMI, TC, and TG in Asian populations ([@b20-molcell-37-6-467]; [@b33-molcell-37-6-467]).

Taken together, our data support the hypothesis that bodyweight may be the major factor in determining serum liver enzyme levels. Moreover, a significantly lower level of Alu methylation was found in overweight participants compared with normal weight or obese participants (p \< 0.0001), but no significant difference was observed between the latter 2 groups, indicating a U-shaped association between Alu methylation and BMI ([Table 2](#t2-molcell-37-6-467){ref-type="table"} and [Fig. 2](#f2-molcell-37-6-467){ref-type="fig"}). After adjusting for other clinical covariates, this association was still found to be significant ([Table 2](#t2-molcell-37-6-467){ref-type="table"}). However, age, smoking status, and alcohol consumption were not significantly associated with Alu methylation levels in blood cells (data not shown). Similarly, previous studies have reported no association between smoking, alcohol consumption, and leukocyte DNA methylation ([@b15-molcell-37-6-467]; [@b18-molcell-37-6-467]; [@b35-molcell-37-6-467]; [@b50-molcell-37-6-467]).

To date, studies of global methylation levels of blood DNA and BMI have yielded inconsistent results ([@b18-molcell-37-6-467]; [@b24-molcell-37-6-467]; [@b26-molcell-37-6-467]; [@b39-molcell-37-6-467]; [@b47-molcell-37-6-467]; [@b48-molcell-37-6-467]; [@b50-molcell-37-6-467]). Most previous studies reported no significant association between BMI and global DNA methylation ([@b18-molcell-37-6-467]; [@b39-molcell-37-6-467]; [@b47-molcell-37-6-467]; [@b48-molcell-37-6-467]; [@b50-molcell-37-6-467]). In contrast, higher BMI has been reported to be associated with lower LINE-1 methylation ([@b24-molcell-37-6-467]; [@b26-molcell-37-6-467]). Notably, we observed that participants with a BMI of 25 to 30 kg/m^2^ had the lowest methylation levels compared with the other groups, and that Alu methylation was elevated among those with a BMI higher or lower than that range. To the best of our knowledge, this is the first study to report a novel U-shaped association between BMI and Alu methylation. Interestingly, the association between BMI and all-cause mortality has previously been shown to be U-shaped, with the concave region corresponding to BMIs of between 22 and 26 kg/m^2^ ([@b4-molcell-37-6-467]; [@b41-molcell-37-6-467]; [@b49-molcell-37-6-467]). Recently, we have observed that persistent organic pollutants, polychlorinated biphenyls are related to MGMT hypermethylation with an inverted U-shaped curve (P for quadratic term \< 0.01). The prevalence of hypermethylation was highest in the subjects in the 2^nd^ quintile (28.4%); however the subjects in the 5^th^ quintile had a low prevalence of hypermethylation (8.2%) (unpublished data). Taken together, these data suggest the biphasic (hermetic) dose response model in which adaptive responses to low doses otherwise harmful conditions improve the functional ability of the cells and organism, resulting in a U or inverted U-shaped dose response ([@b6-molcell-37-6-467]). Accordingly, several lines of evidence are presented that DNA methylation may be an attractive candidate molecular mechanism for hormesis-like response ([@b36-molcell-37-6-467]).

Although the exact mechanism underlying the elevated Alu methylation observed in the blood cells of obese people is not known, several possible explanations have been suggested. First, it is reasonable to speculate that sleeping disturbance might contribute to increases in Alu methylation in obese people. Obstructive sleep apnea (OSA) is highly prevalent among obese patients ([@b46-molcell-37-6-467]) and methylation of the endothelial nitric oxide synthase and forkhead box P3 genes in blood DNA has been shown to be linearly associated with the severity of OSA ([@b17-molcell-37-6-467]; [@b19-molcell-37-6-467]). This suggests that global methylation can be influenced by OSA and other sleep disorders. In support of this theory, we found that scored sleep management was higher in normal and overweight subjects compared with obese ones (data not known), indicating that obese individuals may have poorer sleep quality than non-obese people. Second, although BMI does not differentiate between muscle mass and adipose tissue, people with high BMI can be inferred to have high levels of body fat, causing higher levels of inflammatory markers such as interleukin (IL)-6 ([@b27-molcell-37-6-467]). Moreover, persistent inflammation may cause global DNA hypermethylation in peripheral blood cells *via* IL-6 signaling ([@b32-molcell-37-6-467]). Thus, it is likely that elevated Alu methylation in people with high BMI is a consequence of a low but continuous inflammatory drive of obesity. Third, [@b16-molcell-37-6-467] demonstrated that the expression of DNA methyltransferase 3a is markedly up-regulated in the adipose tissue of obese mice. Similarly, a significantly higher frequency of *RASSF1A*, *p16* and *hMLH1* methylation is observed in nonmalignant tissues of obese patients ([@b25-molcell-37-6-467]; [@b45-molcell-37-6-467]). In light of evidence that tissue-specific methylation profiles are reflected in circulating cell epigenomics ([@b44-molcell-37-6-467]), it is tempting to speculate that obesity can increase global methylation levels in peripheral blood DNA. Fourth, there is compelling evidence that heterogeneity in the number of specific leukocytes has the potential to confound methylation measurements using whole blood DNA and that increased total leukocytes are associated with obesity ([@b34-molcell-37-6-467]; [@b38-molcell-37-6-467]). Thus, a plausible hypothesis is that a progressively uprising trend at high BMI might be due to differential lymphocyte counts associated with adiposity development. In this respect, it is noteworthy that DNA methylation is closely related to lymphocyte count ([@b50-molcell-37-6-467]). Finally, these divergent results may be due to the specific racial/ethnic characteristics of the study population or the small sample size. Studies with a larger sample size are therefore required to confirm these findings. Further studies to confirm the U-shaped association between Alu methylation and BMI by measuring LINE-1 methylation and to understand the biological mechanisms underlying observed relationship are also required.

Collectively, the present study showed a novel U-shaped association between Alu methylation and BMI, suggesting that BMI-global DNA methylation relationship might play a convoluted role in etiology and pathogenesis of obesity as a hermetic dose response. In addition, the correlation could be a potential biomarker for the initial screening of other obesity-related disease. Furthermore, our results showed magnitude of obesity in general healthy population as Korean reproductive aged women.
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###### 

Characteristics of study participants

                                  Normal weight (n = 92)   Overweight (n = 79)   Obese (n = 73)    *F/X^2^*   P-value   *Post hoc* comparison using the Duncan method
  ------------------------------- ------------------------ --------------------- ----------------- ---------- --------- -----------------------------------------------
  Age, years (SD)                 31.52 (8.84)             31.70 (5.52)          32.93 (8.98)      0.72       0.487     
  Smoking status, n (%)                                                                                                 
    Non-smoker                    67 (72.8)                60 (75.9)             52 (71.2)                              
    Former smoker                 6 (6.5)                  6 (7.6)               2 (2.7)           3.51       0.477     
    Current smoker                19 (20.7)                13 (16.5)             19 (26.1)                              
  Alcohol consumption, n (%)                                                                                            
    Non-drinker                   22 (23.9)                23 (29.1)             30 (41.1)         7.58       0.270     
    Ever drinker                  70 (76.1)                56 (70.9)             43 (58.9)                              
  Hemoglobin, % (SD)              11.97 (1.05)             12.23 (0.99)          12.57 (1.22)      6.18       0.002     3 \> 2, 1
  Creatinine, mg/dl (SD)          0.87 (0.12)              0.86 (0.09)           0.87 (0.10)       0.53       0.587     
  Glucose, mg/dl (SD)             93.72 (6.17)             95.57 (23.19)         93.18 (14.18)     0.49       0.611     
  GOT, units/l (SD)               17.50 (4.48)             19.67 (7.17)          24.27 (16.43)     9.08       \<0.001   3 \> 2, 1
  GPT, units/l (SD)               13.36 (8.08)             18.48 (12.58)         29.92 (27.62)     18.80      \<0.001   3 \> 2, 1
  Total bilirubin, mg/dl (SD)     0.62 (0.26)              0.59 (0.30)           0.58 (0.27)       0.71       0.492     
  Total cholesterol, mg/dl (SD)   179.59 (31.66)           190.94 (47.89)        199.08 (30.35)    5.68       0.004     3 \> 2 \> 1
  Triglyceride, mg/dl (SD)        83.93 (46.07)            116.57 (86.88)        168.48 (128.18)   17.92      \<0.001   3 \> 2 ≥ 1

SD, standard deviation; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase

###### 

Correlation between *Alu* methylation and BMI

  Gene                Crude means    Adjusted means[\*](#tfn2-molcell-37-6-467){ref-type="table-fn"}                                     
  ------------------- -------------- ----------------------------------------------------------------- ---------- -------------- ------- ----------
  *Alu* methylation                                                                                                                      
    Normal weight     26.27 ± 0.82   67.46                                                             \< 0.001   26.28 ± 0.09   67.72   \< 0.001
    Overweight        24.96 ± 0.45                                                                                24.95 ± 0.12           
    Obese             25.99 ± 0.94                                                                                25.96 ± 0.10           

Adjusted for clinical laboratory values including hemoglobin, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, total cholesterol, and triglyceride levels. The Bonferroni method was used for post-comparison.
